Cargando…
Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling
BACKGROUND: Site-of-action concentrations for bedaquiline and pretomanid from tuberculosis patients are unavailable. The objective of this work was to predict bedaquiline and pretomanid site-of-action exposures using a translational minimal physiologically based pharmacokinetic (mPBPK) approach to u...
Autores principales: | Mehta, Krina, Guo, Tingjie, van der Graaf, Piet H., van Hasselt, J. G. Coen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042768/ https://www.ncbi.nlm.nih.gov/pubmed/36802057 http://dx.doi.org/10.1007/s40262-023-01217-7 |
Ejemplares similares
-
Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid
por: Timm, Juliano, et al.
Publicado: (2023) -
1400. Pretomanid in the Treatment of Patients with Tuberculosis in the United States: the Bedaquiline, Pretomanid and Linezolid (BPaL) Accelerated Monitoring (BAM) Project
por: Goswami, Neela, et al.
Publicado: (2021) -
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Gómez-González, Paula J., et al.
Publicado: (2021) -
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
por: Oelofse, S., et al.
Publicado: (2021) -
Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
por: Conradie, Francesca, et al.
Publicado: (2020)